XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com. All references to “portfolio” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates in XOMA’s posts strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

With demonstrated clinical development and commercialization expertise, VIVUS is dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases. We develop high-potential molecules that have compelling safety and efficacy potential, and transform them into proprietary products that enable significant advances in patient care and outcomes. We strive to meet our goals of improving patient quality of life, giving healthcare providers new treatment options, providing a collaborative environment for our employees and creating value for our shareholders.

We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be applied across a vast array of indications to create victories for patients most in need.

List Labs specializes in the production of native toxins, recombinant proteins, bacterial fermentation, assay development, contract manufacturing, and biotherapeutics. List Labs produces C. difficile toxin A and toxin B, shiga toxins, cholera toxin, anthrax toxins (PA, LF, and EF), pertussis toxin, diphtheria toxin, CRM197, tetanus toxin, staphylococcal enterotoxin B, botulinum toxins as well as several types of lipopolysaccharides (LPS) or endotoxin for purchase by the research community.

Biotium is a biotechnology company that strives for innovation in biochemicals and fluorescent reagents. Innovation is at the very heart of what Biotium does every day. With 3,000+ fluorescent reagent products, a significant amount of our resources are dedicated to research and development and intellectual property protection. Our efforts have resulted in a growing number of granted and pending patents that cover a number of industry-leading technologies, including: GelRed™ and GelGreen™ nucleic acid gel stains: highly sensitive DNA/RNA gel stains made safe by preventing dye penetration into cells EvaGreen™ DNA-binding Dye: qPCR dye working on a novel “release-on-demand” DNA-binding mechanism; the only dye that works perfectly for both qPCR and highly sensitive melt curve analysis CF™ dyes: A series of 20 highly water soluble dyes with colors spanning the entire visible and near infrared spectra; designed for protein labeling using breakthrough chemistries to produce unrivaled performance in brightness and photostability Mix-n-Stain™ Antibody Labeling Kits: A revolutionary protein labeling technology that allows anyone to optimally label an antibody , with or without the presence of BSA or gelatin, with one of our CF™ dyes or biotin in 30 minutes and ~100% yield. NucView™ Caspase 3/7 Enzyme Substrate: A novel concept to detect caspase activity in live cells by releasing a cell nucleus-staining dye upon substrate cleavage AccuClear™ and AccuBlue™ DNA Quantitation Kits: Kits with the lowest dsDNA detection limit and widest linear range in the market PMA™ DNA Modification Agent: An essential reagent for selective detection of viable pathogens by qPCR

We are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. BioCardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its CardiAMP™ and CardiALLO™ therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. These programs are enabled by the Company's Helix™ transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.

Jaguar Health (NASDAQ: JAGX) (“Jaguar”) is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Napo Pharmaceuticals, a Jaguar company, focuses on developing and commercializing proprietary human pharmaceuticals from plants harvested responsibly from rainforest areas. Jaguar is the majority shareholder of Napo Therapeutics S.p.A., a corporation established by Jaguar in Italy in 2021 that focuses on expanding crofelemer access in Europe. Jaguar Animal Health is a tradename of Jaguar Health. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health, focuses on developing novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (ADHD) in adults. For more information about Jaguar, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo Therapeutics, visit napotherapeutics.com. For more information about Magdalena Biosciences, visit magdalenabiosciences.com. To read our full social media policy, please visit https://jaguar.health/social-media-policy

ReCarbon, Inc. is the creator of ReCarbon™, an innovative technology platform that recycles carbon emissions into revenue generating byproducts. We specialize in building proprietary plasma generation systems that convert industrial carbon emissions into industrial source gases. Our goal is to provide technologies that reduce carbon emissions, recycle emissions into valuable byproducts, and enable revenue growth.

Calera Corporation is dedicated to reversing global warming by capturing and permanently storing greenhouse gases in the built environment. Inspired by nature, Calera's process converts carbon dioxide (CO2) into a novel cement product at lower cost than traditional Portland cement. Calera is based in Campbell California. To learn more about Calera, please visit http://www.calera.com.

Born on a relief mission, DripDrop is committed to defeating dehydration. When you stick to your mission, we stick to ours. As an oral rehydration solution (ORS), every stick of DripDrop ORS is meticulously formulated for fast absorption, with 1/2 the sugar and 3x the electrolytes of sports drinks. Everything you need, nothing you don't. #StickToYourMission

Polaris Pharmaceuticals, is a biopharmaceutical development and manufacturing organization (CDMO) specializing in biologics derived from microbial systems. We have manufactured clinical material for trials in the United States, Europe, China, Taiwan, Australia, and Korea. Polaris Pharma offers a comprehensive range of process and analytical development and high-quality cGMP pre-clinical and clinical manufacturing services. We offer services for the following: • Process Development • Master and Working Cell Bank Propagation • Pre-Clinical/Clinical Manufacturing • QC Method Development • In Process Testing • Release Testing • Stability Storage and Testing • Availability to provide high purity WFI and PW • Custom Buffer and Media Manufacturing • Contract Filling, Labeling, Inspection • Microbial Based Fermentation Products

Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for the treatment of cancer with an emphasis on new immuno-oncology products designed to harness the patient’s immune system to combat and eradicate cancer. Its lead immuno-oncology drug candidate, sotigalimab, is a potent immune-activating antibody against CD40 currently in Phase 2 clinical development.